Invivyd, Inc. (IVVD)
NASDAQ: IVVD · Real-Time Price · USD
0.6150
+0.0150 (2.50%)
Mar 31, 2025, 2:23 PM EDT - Market open
Invivyd Revenue
In the year 2024, Invivyd had annual revenue of $25.38M. Invivyd had revenue of $13.82M in the quarter ending December 31, 2024.
Revenue (ttm)
$25.38M
Revenue Growth
n/a
P/S Ratio
2.80
Revenue / Employee
$253,840
Employees
100
Market Cap
73.78M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25.38M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
IVVD News
- 4 days ago - Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors - GlobeNewsWire
- 11 days ago - Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights - GlobeNewsWire
- 26 days ago - Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1 - GlobeNewsWire
- 5 weeks ago - FDA Rejects Invivyd's Request To Expand Emergency Authorization For Preventive COVID-19 Antibody For Immunocompromised Patients - Benzinga
- 5 weeks ago - FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients - GlobeNewsWire
- 7 weeks ago - Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 - GlobeNewsWire
- 7 weeks ago - Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold - GlobeNewsWire
- 7 weeks ago - I See The Bull Case For Invivyd, But I'm Not Married To It - Seeking Alpha